New hepatitis b pill shows promise in large trial
NCT ID NCT07203118
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 18 times
Summary
This study tests a new oral medication, hepenofovir fumarate, for people with chronic hepatitis B. It involves 1444 adults aged 18-65 who have not been treated before or have stopped treatment. The goal is to find the best dose that controls the virus safely, compared to an existing drug called TAF.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
Jilin, changchun, China
Conditions
Explore the condition pages connected to this study.